Search results for "androgen"

showing 10 items of 326 documents

Effect of two xeno-hormones, genistein and vinclozolin on development and exocrines and endocrines functions of submandibular salivary glands of Wist…

2012

The salivary glands are mixed glands: saliva (exocrine product) is involved inmaintaining oral homeostasis whereas endocrine secretions (eg growth factors) have aphysiological role (gametogenesis, osteogenesis, hypertension ..). In mammals, they displaysexual dimorphism suggesting a possible susceptibility to xeno-hormones.This manuscript presents the action of genistein (phytoestrogen) and/or vinclozolin (antiandrogenic)on the submandibular gland (SM) rats when performing an early exposure via themother (pregnancy, lactation) or an exposure during the growth period (from weaning toadulthood). The SM glands, collected at immature and young adult ages, have been analyzedaccording histologica…

NGFSweet Preference[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyProgesterone ReceptorRécepteur ProgestéroneMucin 10Préférence au sucréCystatine CRécepteur AndrogèneTGFAndrogen receptorMucine 10GustineGranular Convoluted TubuleCystatin CEGF
researchProduct

A putative social chemosignal elicits faster cortical responses than perceptually similar odorants.

2006

Social chemosignals, so-called pheromones, have recently attracted much attention in that effects on women's psychophysiology and cortical processing have been reported. We here tested the hypothesis that the human brain would process a putative social chemosignal, the endogenous steroid endrostadienone, faster than other odorants with perceptually matched intensity and hedonic characteristics. Chemosensory event-related potentials (ERP) were recorded in healthy women. ERP analyses indicate that androstadienone was processed significantly faster than the control odorants. Androstadienone elicited shorter latencies for all recorded ERP components but most so for the late positivity. This fin…

Olfactory systemVisual perceptionMotion PerceptionCortical processingPheromoneschemistry.chemical_compound0302 clinical medicineAttentionHydrogen SulfideEvoked PotentialsCerebral Cortex0303 health sciencesBrain MappingAndrostadienoneElectroencephalographyHuman brainOlfactory PathwaysMiddle AgedChemoreceptor CellsSmellmedicine.anatomical_structureNeurologyPattern Recognition VisualSex pheromoneSensory Thresholds[ SCCO.NEUR ] Cognitive science/NeuroscienceAndrogensFemalePsychologyERPpsychological phenomena and processesAdultCognitive NeuroscienceOlfactionAndrosterone03 medical and health sciencesmedicinePsychophysicsReaction TimeHumansSocial Behavior030304 developmental biologyCommunicationDose-Response Relationship Drugbusiness.industry[SCCO.NEUR]Cognitive science/NeuroscienceOlfactionAndrostadienesPsychophysiologychemistrybusinessNeuroscience030217 neurology & neurosurgeryPsychomotor PerformanceNeuroImage
researchProduct

The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Pro…

2017

Abstract Background The androgen receptor splice variant 7 (AR-V7) is associated with resistance to hormonal therapy in castration-resistant prostate cancer (CRPC). Due to limitations of the methods available for AR-V7 analysis, the identification of a reliable detection method may facilitate the use of this biomarker in clinical practice. Objective To confirm AR-V7 as a predictor of resistance to hormonal therapy and develop a new approach to assess AR-V7 by highly sensitive digital droplet polymerase chain reaction (ddPCR) in plasma-derived exosomal RNA. Design, setting, and participants Plasma samples were collected from 36 CRPC patients before they began second-line hormonal treatment. …

Oncology0301 basic medicineMaleResistanceExosomeschemistry.chemical_compoundProstate cancer0302 clinical medicineProtein IsoformsNeoplasm MetastasisReceptorAged 80 and overProstate cancerMiddle AgedProstatic Neoplasms Castration-ResistantReceptors Androgen030220 oncology & carcinogenesisBenzamidesAdenocarcinomaBiomarker (medicine)Hormonal therapyAR-V7; Digital droplet PCR; Exosomes; Hormonal therapy; Pharmacogenetics; Prostate cancer; Resistance; UrologyAndrostenesHormonal therapymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.drug_classUrologyCastration resistantAdenocarcinomaDisease-Free Survival03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicineNitrilesPhenylthiohydantoinmedicineEnzalutamideHumansAgedDigital droplet PCRPlasma derivedbusiness.industryRNAAndrogen Receptor Splice Variant 7medicine.diseaseAndrogenEndocrinology030104 developmental biologychemistryPharmacogeneticsDrug Resistance NeoplasmCancer cellCancer researchRNAAR-V7businessPharmacogenetics
researchProduct

Expression of sexual hormones receptors in oral squamous cell carcinoma.

2011

Sexual hormones play an important role in expression of genes involved in a wide variety of biological and neoplastic processes. The information on Estrogen Receptors (ER) expression in non-target tissues is very few and, in particular, the studies in head and neck tumors are still controversial. Recent studies analyzed the role of Tamoxifen (TAM) on Oral Squamous Cell Carcinoma (OSCC) lines in relation to the presence/absence of ER. The purpose of the present study was to evaluate the expression of sexual hormones receptors mRNAs, in particular Estrogen Receptor alpha (ERα) and Androgen Receptor (AR) mRNA in OSCC tissues. The study group comprised 20 samples of OSCC, harvested from 20 oth…

OncologyAdultMalemedicine.medical_specialtyImmunologyEstrogen receptorBiologyOral Squamous Cell CarcinomaSettore MED/28 - Malattie OdontostomatologicheEstrogen ReceptorsInternal medicinemedicineCarcinomaImmunology and AllergyHumansAndrogen Receptors; Estrogen Receptors; Oral Squamous Cell Carcinoma;Oral mucosaReceptorAgedPharmacologyOral squamous cell carcinoma estrogen receptorsAndrogen receptorEstrogen Receptor alphaCancerMiddle Agedmedicine.diseaseAndrogen receptormedicine.anatomical_structureReceptors AndrogenCase-Control StudiesCancer researchCarcinoma Squamous CellFemaleMouth NeoplasmsEstrogen receptor alphaTamoxifenmedicine.drugSexual hormones OSCCAndrogen Receptors
researchProduct

Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review.

2020

Abstract Context Optimal management of prostate cancer (PCa) patients with lymph node invasion at radical prostatectomy and pelvic lymph node dissection still remains unclear. Objective To assess the effectiveness of postoperative treatment strategies for pathologically node-positive PCa patients. The secondary aim was to identify the most relevant prognostic factors to guide the management of pN1 patients. Evidence acquisition A systematic review was performed in January 2020 using Medline, Embase, and other databases. A total of 5063 articles were screened, and 26 studies including 12 537 men were selected for data synthesis and included in the current review according to the Preferred Re…

OncologyBiochemical recurrenceMalemedicine.medical_specialtyUrologymedicine.medical_treatment030232 urology & nephrologyContext (language use)PelvisAndrogen deprivation therapy03 medical and health sciencesProstate cancer0302 clinical medicinePositive nodesInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingStage (cooking)ProstatectomyProstate cancerbusiness.industryProstatectomyLymph node; Positive nodes; Prostate cancer; Radical prostatectomyProstatic Neoplasmsmedicine.diseaseRadical prostatectomyRadiation therapySystematic reviewOncology030220 oncology & carcinogenesisLymphatic MetastasisLymph Node ExcisionSurgeryLymph nodebusinessEuropean urology oncology
researchProduct

The management of prostate cancer in patients with a rising prostate-specific antigen level

2000

OncologyGynecologyChemotherapymedicine.medical_specialtyProstatectomymedicine.drug_classbusiness.industryUrologymedicine.medical_treatmentAntiandrogenManagement of prostate cancerRadiation therapyProstate-specific antigenmedicine.anatomical_structureProstateInternal medicinemedicineIn patientbusinessBJU international
researchProduct

Moderate hypofractionated helical tomotherapy for prostate cancer in a cohort of older patients: a mono-institutional report of toxicity and clinical…

2019

Purpose or objective: To evaluate toxicity and outcomes of moderately hypofractionated helical tomotherapy for the curative treatment of a cohort of patients aged ≥ 75 years with localized prostate cancer (PC). Materials and methods: From January 2013 to February 2017, 95 patients with median age 77 years (range 75–88) were treated for PC. 39% were low risk, 33% intermediate risk (IR), 28% high risk (HR). Median iPSA was 9.42 ng/ml (1.6–107). Androgen deprivation was prescribed according to NCCN recommendations. All patients received 70 Gy in 28 fractions to the prostate; 61.6 Gy were delivered to the seminal vesicles for IR; whole pelvis irradiation with a total dose of 50.4 Gy was added i…

OncologyMaleAgingmedicine.medical_specialtymedicine.medical_treatmentTomotherapyCohort Studies03 medical and health sciencesProstate cancer0302 clinical medicineQuality of lifeStatistical significanceInternal medicinemedicineHumans030212 general & internal medicineAgedAged 80 and overbusiness.industryProstatic NeoplasmsAndrogen AntagonistsMiddle Agedprostate cancermedicine.diseaseRadiation therapyTreatment OutcomeToxicityCohortQuality of LifeRadiotherapy Intensity-ModulatedGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryCohort studyAging clinical and experimental research
researchProduct

Carcinoma of the prostate. Guidelines for treatment: the role of antiandrogens.

1990

Our preliminary experience shows that flutamide is effective in patients with stage C or D prostate cancer. Local and distant response rates are comparable to those obtained with "classic" hormone therapy. Libido and sexual potency generally are unaffected. Palliation of symptoms, which is frequent, is usually accompanied by improved performance status and quality of life. Side effects are slight or moderate, but elevated transaminase levels in patients with borderline liver insufficiency are possible.

OncologyMalemedicine.medical_specialtyAntiandrogensmedicine.medical_treatmentUrologyImidazolidinesGeneral Biochemistry Genetics and Molecular BiologyFlutamideProstate cancerchemistry.chemical_compoundHistory and Philosophy of ScienceProstateInternal medicinemedicineCarcinomaHumansLibidobusiness.industryGeneral NeuroscienceCarcinomaImidazolesProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseFlutamidemedicine.anatomical_structurechemistryElevated transaminasesHormone therapybusinessAnnals of the New York Academy of Sciences
researchProduct

A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

2012

BACKGROUND: Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of BEs when diagnosed. The results of a randomized study comparing TAM prophylaxis vs. TAM therapy are presented. METHODS: One hundred seventy-six patients with prostate cancer (PC) who were candidates for bicalutamide monotherapy were randomized to receive TAM 20 mg daily orally within 1 month from the onset of BEs (arm A) vs. TAM 10 mg daily starting simultaneously with bical…

OncologyMalemedicine.medical_specialtyBicalutamidemedicine.drug_classVisual analogue scaleUrologyBreast painBreast painAntineoplastic AgentsAntiandrogenStatistics Nonparametriclaw.inventionTosyl CompoundsProstate cancerstomatognathic systemRandomized controlled trialBicalutamidelawInternal medicineNitrilesmedicineHumansAnilidesskin and connective tissue diseasesAgedAged 80 and overProstate cancerbusiness.industryEstrogen AntagonistsProstatic NeoplasmsMiddle Agedmedicine.diseaseAntiandrogenTamoxifenTreatment OutcomeOncologyGynecomastiaChemotherapy AdjuvantGynecomastiamedicine.symptombusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugClinical genitourinary cancer
researchProduct

PSA and second-line therapy of hormone refractory prostate carcinoma

2001

The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was 4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient. Copyright © 2001 S. Karger AG, Basel.

OncologyMalemedicine.medical_specialtyPathologyHormone refractorymedicine.drug_classUrologyAdenocarcinomaAntiandrogenSettore MED/24 - UrologiaPSAProstateInternal medicineCarcinomamedicineHumansHormone refractoryBone painAgedAged 80 and overPerformance statusbusiness.industryProstateProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseProstate-specific antigenmedicine.anatomical_structureProstatic adenocarcinomaAdenocarcinomamedicine.symptombusiness
researchProduct